Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Lancet., Jul;378(9787):229-37 (2011)
Successful HIV treatment: lessons learned.
J Manag Care Pharm., Sep;12(7 Suppl B):S6-11 (2006)
Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study.
HIV Clin Trials., 8(1):19-23 (2007)
Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial.
AIDS., Jan;23(3):423-6 (2009)
Tai Chi for osteopenic women: design and rationale of a pragmatic randomized controlled trial.
BMC Musculoskelet Disord., 11:40 (2010)
A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.
AIDS., Mar;16(4):579-88 (2002)
Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen.
J. Acquir. Immune Defic. Syndr., Sep;37(1):1140-6 (2004)
Impact of Tai Chi exercise on multiple fracture-related risk factors in post-menopausal osteopenic women: a pilot pragmatic, randomized trial.
BMC Complement Altern Med., 12:7 (2012)
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
J. Acquir. Immune Defic. Syndr., May;60(1):33-42 (2012)
Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir).
J Clin Pharmacol., Apr;50(4):392-400 (2010)
Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
Arch. Intern. Med., Apr;162(8):921-8 (2002)
Pediatrics in an inner city environment: a practice responds to the challenges of the 1990s.
J Ambul Care Manage., Jan;16(1):42-8 (1993)
Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis.
J. Acquir. Immune Defic. Syndr., 4(5):521-31 (1991)
The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction.
Proc. Natl. Acad. Sci. U.S.A., Dec;98(26):15191-6 (2001)
CD4+ count-guided interruption of antiretroviral treatment.
N. Engl. J. Med., Nov;355(22):2283-96 (2006)
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.
Ann. Intern. Med., Sep;149(5):289-99 (2008)
Treatment problems in endometrial cancer.
Clin Obstet Gynecol., Sep;10(3):625-40 (1967)
Leukocyte migration enhancement as an indicator of immunologic enhancement. I. Pregnancy.
Am. J. Obstet. Gynecol., Jan;136(1):1-4 (1980)
Feasibility of intraoperative administration of chemotherapy for gynecologic malignancies: assessment of acute postoperative morbidity.
Gynecol. Oncol., Feb;48(2):227-31 (1993)
Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis.
J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., Aug;15(4):275-82 (1997)
Evaluation of simplified protease inhibitor dosing regimens for the treatment of HIV infection.
AIDS Read., May;10(5):296-9, 304-7, 311-3 (2000)
Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection.
Ann. Intern. Med., Sep;133(6):430-4 (2000)
The cost effectiveness of combination antiretroviral therapy for HIV disease.
N. Engl. J. Med., Mar;344(11):824-31 (2001)
Multiple regions within the coxsackievirus and adenovirus receptor cytoplasmic domain are required for basolateral sorting.
J. Biol. Chem., Jul;276(27):25392-8 (2001)
Critical role for CD8 in binding of MHC tetramers to TCR: CD8 antibodies block specific binding of human tumor-specific MHC-peptide tetramers to TCR.
J. Immunol., Jul;167(1):270-6 (2001)
Controversies in AIDS treatment. Proceedings from CME conference sponsored by Cornell University Medical College and the American Foundation for AIDS Research (AmFAR). November 8, 1997. Question and answer session.
AIDS Patient Care STDS., Jul;12(7):557-66 (1998)